BSE filing, NSE: NOVARTIND. Summary written from the filing by ALFA Finder's alert engine.
Novartis India Ltd: key numbers
- Share price
- ₹1,736.60
- Market cap
- ₹4,288 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- -1074.6×Sector 37.9×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Evonile Pharma Fund Raise of ₹900 Cr
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
- Value
- ₹900.0 Cr
Evonile Pharma Capital Structure Change
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
- Value
- ₹884.8 Cr
- Execution
- Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026
Evonile Pharma Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹56.1 cr (-38% YoY) and PAT loss ₹77.5 cr, including ₹68 cr exceptional items. H1 revenue ₹159.9 cr (-10%). Transitioning to an independent branded pharma model; Minipress XL acquired.
Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr
Other capital structure change announcements
All →Jyothy Labs Capital Structure Change
Jyothy Labs' board approved a Rs 147 Crore share buyback via tender offer at Rs 215 per share. The record date is November 11, 2026.
- Value
- ₹147.0 Cr
Share India Securities Capital Structure Change
Share India Securities allotted 44,02,000 equity shares under its Silverleaf Capital amalgamation scheme. It also granted 3,80,500 employee stock options under ESOS-II.
Arvaya Healthcare Capital Structure Change
Arvaya Healthcare's board approved the draft letter of offer for a rights issue of partly paid-up equity shares up to ₹210 Crore, plus a postal ballot. The board outcome's main decision is the rights issue, so it is classified as a capital raise step.
- Value
- ₹210.0 Cr
Mittal Life Style Capital Structure Change
Mittal Life Style set 15 December 2026 as the record date for a 10:1 consolidation of its equity shares. No cash is paid.
Zodiac JRD MKJ Capital Structure Change
Zodiac-JRD-MKJ approved final terms of its Rs 40 crore rights issue at Rs 25 per share. Issue runs 19 November to 3 December 2026.
- Value
- ₹40.00 Cr
Baba Arts Capital Structure Change
Skybridge Interactive LLP, a non-promoter acquirer, disclosed under Reg 29(2) that it acquired 65,00,000 shares of Baba Arts, raising its stake from 62.28% to 74.67%. The acquisition was off-market under a share purchase agreement dated 25 February 2026.